COMP <GO>
UTHR vs ZTS // 10Y YIELD & FRED MACRO BETA
United Therapeutics Corporation (NASDAQ) VS. Zoetis Inc. (NYSE) • 15-METRIC TALLY: UTHR 7
— ZTS 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: ZTS
LAST: $598.72 (+0.87%) • MKT CAP: $25.68B
macro-sensitivity
0.95
LAST: $79.72 (+1.17%) • MKT CAP: $32.94B
macro-sensitivity
0.99
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. ZTS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | ZTS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 71.80% | +16.10 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | 25.70% | -5.60 | ZTS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 10.3x | +2.20 | ZTS | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 7.01% | -2.92 | ZTS | /fcf-yield <GO> |
| Operating Margin | 46.90% | 34.40% | +12.50 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 41.90% | 28.20% | +13.70 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | 2.30% | +8.30 | UTHR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 4.53 | +17.99 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 59.6 | +9.00 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.95 | 0.99 | -0.04 | ZTS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.8x | 11.3x | +6.50 | ZTS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.68B | $32.94B | -$7.26B | ZTS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | ZTS REV | UTHR GROSS % | ZTS GROSS % | UTHR FCF | ZTS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $9.47B | 87.9% | 71.8% | $1.04B | $2.28B |
| FY 2024 | $2.88B | $9.26B | 89.2% | 70.6% | $1.08B | $2.30B |
| FY 2023 | $2.33B | $8.54B | — | — | $873.3M | $1.97B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
ZTS // BETA 0.99